153 related articles for article (PubMed ID: 21689426)
21. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
22. A machine learning approach to identify predictive molecular markers for cisplatin chemosensitivity following surgical resection in ovarian cancer.
Shannon NB; Tan LLY; Tan QX; Tan JW; Hendrikson J; Ng WH; Ng G; Liu Y; Ong XS; Nadarajah R; Wong JSM; Tan GHC; Soo KC; Teo MCC; Chia CS; Ong CJ
Sci Rep; 2021 Aug; 11(1):16829. PubMed ID: 34413360
[TBL] [Abstract][Full Text] [Related]
23. Imaging VCAM-1 as an indicator of treatment efficacy in metastatic ovarian cancer.
Scalici JM; Thomas S; Harrer C; Raines TA; Curran J; Atkins KA; Conaway MR; Duska L; Kelly KA; Slack-Davis JK
J Nucl Med; 2013 Nov; 54(11):1883-9. PubMed ID: 24029657
[TBL] [Abstract][Full Text] [Related]
24. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
25. Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma.
Eltabbakh GH
J Surg Oncol; 2000 Mar; 73(3):148-52. PubMed ID: 10738268
[TBL] [Abstract][Full Text] [Related]
26. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
27. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
Yoshihara M; Kajiyama H; Yokoi A; Sugiyama M; Koya Y; Yamakita Y; Liu W; Nakamura K; Moriyama Y; Yasui H; Suzuki S; Yamamoto Y; Ricciardelli C; Nawa A; Shibata K; Kikkawa F
Int J Cancer; 2020 Apr; 146(8):2268-2280. PubMed ID: 31904865
[TBL] [Abstract][Full Text] [Related]
29. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
Sevin BU; Perras JP
Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary.
Balat O
Eur J Gynaecol Oncol; 2004; 25(2):195-6. PubMed ID: 15032280
[TBL] [Abstract][Full Text] [Related]
31. Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro.
Weinreich J; Struller F; Sautkin I; Giuashvili S; Reymond M; Königsrainer A; Schott TC
Invest New Drugs; 2019 Jun; 37(3):415-423. PubMed ID: 30019100
[TBL] [Abstract][Full Text] [Related]
32. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance.
See HT; Freedman RS; Kudelka AP; Burke TW; Gershenson DM; Tangjitgamol S; Kavanagh JJ
Int J Gynecol Cancer; 2005; 15(2):209-16. PubMed ID: 15823101
[TBL] [Abstract][Full Text] [Related]
33. [A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
Gao YT; Wu LY; Zhang W; Zhao D; Li N; Tian HM; Wang XB; Li M; Sun YC; Li N; Li XG
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):358-63. PubMed ID: 24016479
[TBL] [Abstract][Full Text] [Related]
34. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
35. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Molucon-Chabrot C; Isambert N; Benoit L; Zanetta S; Fraisse J; Guilland JC; Royer B; Monin-Baroille P; Flesch M; Fargeot P; Coudert B; Mayer F; Fumoleau P; Chauffert B
Anticancer Drugs; 2006 Nov; 17(10):1211-7. PubMed ID: 17075321
[TBL] [Abstract][Full Text] [Related]
38. PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
Bekos C; Pils D; Dekan S; Hofstetter G; Horak P; Reinthaller A; Polterauer S; Schwameis R; Aust S
Sci Rep; 2021 Mar; 11(1):6400. PubMed ID: 33737722
[TBL] [Abstract][Full Text] [Related]
39. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
[TBL] [Abstract][Full Text] [Related]
40. ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.
Chebouti I; Kuhlmann JD; Buderath P; Weber S; Wimberger P; Bokeloh Y; Hauch S; Kimmig R; Kasimir-Bauer S
Oncotarget; 2017 Apr; 8(15):24303-24313. PubMed ID: 28388557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]